News and Announcements
DMX-200 Phase 2a trial meets primary end point for Chronic Kidney Disease
- Published July 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
DMX-200 is an adjunct therapy in which patients who are already on the standard of care angiotensin II type I receptor blocker (irbesartan) are also dosed with a chemokine receptor CCR2 blocker (propagermanium).
This Phase 2a trial was a dose escalation study in 27 patients with chronic kidney disease of a variety of causes. The primary end point was safety, with changes in biomarkers such as excess protein in the urine (proteinuria) as secondary end points. Proteinuria is a common symptom of kidney disease and is prognostic of deterioration of kidney function. High levels of protein in the urine also exacerbate the inflammation component of kidney disease, setting up a vicious cycle of disease progression.
The data released on the 12th of July from the DMX-200 Phase 2a trial was that DMX-200 has demonstrated safety and tolerability in this diverse patient population, and that in some patient groups the clinically meaningful result of 50% reduction in proteinuria was seen. This reduction was over and above the best response the patients had achieved on the standard of care therapy. These data provide the company with a wealth of information to design a more targeted Phase 2b efficacy study, and deepen engagement with potential licensing partners.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
